Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

SaltX Technology presents successful results for the Calix charging reactor in Bollmora

Energy storage company SaltX Technology is pleased to announce the successful installation and commissioning of a charging reactor from the Australian company Calix Limited (ASX:CXL) at SaltX´s pilot plant in Bollmora, Stockholm. Tests from the pilot plant charging reactor show good results.SaltX has developed a technology that enables efficient peak shifting, to take advantage of the excess renewable energy available during the days or even seasons and shift its availability to the high demand evening and winter periods. SaltX’s patented energy storage solution utilizes the charging

DBP International AB: Japanese patent for Temodex / SI-053 is granted

Double Bond Pharmaceutical International AB (publ) ("DBP" or "The Company", org. No. 556991-6082) has today, February 11th 2022, received information about the granting of a Japanese patent application concerning the company's front-line product Temodex / SI-053. Patent approval provides protection for the technology and the product in Japan until at least 2036. "This is a very important milestone in the development of SI-053 as Japan is one of the biggest markets where we plan to expand the global commercialization of the product," comments Igor Lokot, CEO of DBP. – “We also have

Photocure Partner Asieris announces Approval to conduct a Phase III Clinical Trial for Hexvix in China

Oslo, Norway, February 11, 2022: Photocure ASA (PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has obtained the Phase III clinical trial application (CTA) approval from the National Medical Products Administration (NMPA) of China for Hexvix[®].The study is a prospective, multicenter bridging trial aimed to investigate the additional detection rate and safety of Hexvix[®] and blue light cystoscopy (BLC[®]) versus white light cystoscopy in Chinese patients with non-muscle invasive bladder cancer (NMIBC, tumor types CIS, Ta, T1). The

Vattenfall to redeem hybrid bonds

Vattenfall will on 19 March and 29 March 2022 redeem two outstanding hybrid bonds originally issued in 2015Vattenfall has today given notice that two outstanding SEK denominated hybrid bonds (ISIN number XS1205627547 and XS1205625251), originally issued on 19 March 2015, will be redeemed in accordance with their terms on 19 March 2022 and 29 March 2022 respectively. The bonds to be redeemed have been replaced by three new hybrid bonds issued in the first half of 2021. For more information about Vattenfall’s outstanding bonds, please visit http://corporate.vattenfall.com/investors/

Alfa Laval issues corporate bonds

Alfa Laval – a world leader in heat transfer, centrifugal separation and fluid handling – has raised EUR 600 million in the corporate bond market, under an existing EMTN program. The bonds will be listed on the Irish Stock Exchange.Alfa Laval has issued two corporate bonds of EUR 300 million each, under the company’s existing EMTN program. The bonds will have four- and seven-years maturity respectively, i.e. with maturity on February 18, 2026 and on February 18, 2029. The four-year bonds carry a coupon of 0.875 percent annually and the seven-year bonds carry a coupon of 1.375 percent

Northbaze Distribution announces distribution partnership with Ingram Micro B.V.

Gothenburg, February 11, 2022 – Northbaze Distribution, part of Northbaze Group AB (Publ.) (” Northbaze”) is announcing the company has signed an agreement with Ingram Micro B.V., to distribute products from Northbaze in the Benelux.Northbaze, a Swedish company focusing on mobile accessories with brands such as Copter, Krusell, Kavaj and Jays within its range is further strengthening its presence on the Dutch market by agreeing to start a partnership with leading distributor Ingram Micro B.V. in a strong market for audio and mobile accessories. In joining forces with Ingram Micro B.V.,

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 38 - 11 FEBRUARY 2022 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 75/2021. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information:Thomas France, Investor Communications Partner, tel.: 3315 0451

Elkem ASA – Sale of shares under share incentive programme

Oslo, 11 February 2022 Reference is made to the stock exchange release on 10 February 2022, regarding exercise of share options under Elkem ASA's ("Elkem" or the "Company", OSE ticker code: "ELK") share incentive programme. Pursuant to the sales process conducted by a third party these primary insiders have sold the following number of option shares at a price of NOK 35.3286 per share:   · Inge Grubben-Strømnes (SVP Silicon Products), sold 50,000 shares at a price of 35.3286 per share, following which he holds 850,000 options and 35,189 shares in the Company, Further details

ContextVision – Information regarding dividend and reverse share split in Inify Laboratories

ContextVision AB ("ContextVision" or the "Company") will, in accordance with the press release published on 2 February 2022, distribute all shares in its wholly-owned subsidiary INIFY Laboratories AB ("INIFY") to the shareholders of ContextVision. The shares in INIFY are expected to be delivered to shareholders who have their shares registered at Euroclear Sweden AB around 11 February 2022. Shareholders who have their shares registered at Norska Verdipapirsentralen (VPS), can expect the shares in INIFY to be delivered around 15 February 2022. Following the dividend, a reverse share

Nordnet presents updated financial targets

Today Nordnet presents updated medium-term financial targets. At the capital markets day that the company is arranging today, Nordnet’s CEO and executive management will give additional insights into ongoing business and strategy, as well as commenting on these new financial targets.Nordnet’s updated medium-term financial targets are as follows: · Around 15 percent annual customer growth. · Average savings capital per customer (defined as average quarterly savings capital per customer over the last twelve months) of around SEK 450,000. · Income in relation to savings capital (

NCC to construct another house by the water in Hellerup for Danica

NCC has been commissioned by Danica to construct a third house in Tuborg Strandeng, Hellerup, Denmark. The project is named Kysthus III and will contain 38 apartments and is a continuation of Kysthus I and Kysthus II which the parties previously built together in the same area. The order value amounts approximately SEK 540 million. “We are glad to have been appointed to continue the expansion of the area. Kysthus III gets the same sculptural look as the previous houses and a spectacular view of Öresund and Copenhagen. A building out of the ordinary, says Catarina Molén-Runnäs,

Correction – Biotage and dividend proposal in the Swedish public announcement

Because of a typo, the board proposal for 2021 dividend is stated as 1 krona and 50 öre in this morning’s Swedish public announcement, correct number is 1 krona and 55 öre in accordance with the full year end report 2021.  This information was submitted for publication, through the agency of the contact persons set out above, at immediate publication on 11 February 2022.  About BiotageBiotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development, analytical testing and

Marell develops hybrid interceptor in partnership with Scania

Marell Boats and Scania Power Solutions accelerate the development of next generation sustainable and technologically advanced vessels as they prepare the launch of the M17 Patrol with a hybrid driveline. The companies are collaborating to create a sustainable and state-of-the-art vessel to meet the increased demand for hybrid solutions. This is a unique partnership covering development, testing, and marketing. The objective is to lead the shift towards a sustainable maritime transport system.The M17 Patrol will become the most energy efficient hybrid high-speed craft in the commercial

Wihlborgs’ 2021 year-end report will be presented on 15 February 2022 – invitation to presentation

On Tuesday 15 February 2022, at 7:30 a.m. (CET), Wihlborgs’ 2021 year-end report will be published. Wihlborgs invites press, investors and analysts to a webcast and telephone conference at 9:00 a.m. (CET) on the same date.During the webcast and telephone conference, Ulrika Hallengren, CEO of Wihlborgs, and Arvid Liepe, CFO, will present Wihlborgs’ 2021 year-end report. Following the presentation, there will be the opportunity to pose questions. The presentation will be held in English.  Date:             15 FebruaryTime:             The report will be published at 7:30 a.m. (CET)

TOMRA: Invitation to Q4 2021 Presentation

TOMRA's fourth quarter 2021 results will be released Wednesday 23 February 2022. President & CEO Tove Andersen and CFO Espen Gundersen will present the results at 08:00 CET (UTC+1). The presentation will be sent via live webcast. Questions to the speakers can be directed using the Q&A-tool embedded in the webcast and will be addressed towards the end of the presentation. A recorded version of the webcast will be available shortly after the webcast has concluded. Link to webcast will be available on www.tomra.com (Investor Relations section). https://www.tomra.com/en/investor-

Conversion of paid subscribed units (BTU) into shares and warrants

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, SOUTH AFRICA, CANADA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.   Brighter AB (publ) (“Brighter” or the “Company”) has completed a rights issue of units of maximum approximately SEK 117 million (the “Rights Issue”). The Rights Issue was subscribed to a total of 85.4 percent. A total of 166,666,667 units were issued in the Rights Issue, corresponding to 333,333,334 shares, 333,333,

Nomination Committee proposal for Board of Directors of Diös Fastigheter AB (publ)

Prior to the Annual General Meeting of Diös Fastigheter AB (publ) on April 5, 2022, the Nomination Committee hereby announces its proposal regarding the Chairman of the Board and other Board members.The Nomination Committee propose: · re-election of Bob Persson, Ragnhild Backman, Anders Nelson, Peter Strand and Tobias Lönnevall. Eva Nygren has declined re-election, · to elect Erika Olsén as a new Board member · to elect Bob Persson as Chairman of the Board Erika Olsén was born in 1976 and holds a MSc in Real Estate and Economics from the Royal Institute of

BioStock: CombiGene’s CEO gives business development update

CombiGene’s pilot study, which is aimed at optimising the administration of the drug candidate CG01, has given the company valuable insights for future development steps. The path towards clinical studies, which will take place with support from partner Spark Therapeutics, thus takes another step forward. BioStock contacted the company’s CEO Jan Nilsson who talks about the collaboration with Spark, and how the company views its intensified investment in business development.Read the full interview with Jan Nilsson at biostock.se: https://www.biostock.se/en/2022/02/combigenes-ceo-gives-

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release February 11, 2022 at 9:45 a.m. Nokian Tyres has received an announcement from BlackRock, Inc. on February 10, 2022, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement BlackRock, Inc.'s total holding in Nokian Tyres shares exceeded the level of 5% of the share capital in Nokian Tyres plc, as a result of share transactions concluded on February 9, 2022. BlackRock, Inc. and its funds held on deal date a total of 6,954,281 Nokian Tyres’ shares representing 5.00% of the company’s 138,921,750

BioStock: Respiratorius raises 45 MSEK and prepares COPD project spinoff

Lund-based Respiratorius has announced carrying out a fully guaranteed rights issue to raise 45 MSEK. A majority of the capital will be allocated to finance the continued development of the COPD project RCD405, as the company eyes spinning off the project. Another large part of the funds will go towards preparing for an upcoming phase III study with VAL001 for the treatement of diffuse large-cell B-cell lymphoma, as the company gears up for selling the project.Read the full article at biostock.se:https://www.biostock.se/en/2022/02/respiratorius-raises-45-msek-and-prepares-copd-project-

Prevas Year-End Report 2021

Prevas reaches all-time highs.Proposed dividend 3.50 SEK/share (2.0) October - December 2021 · Net turnover 319.9 MSEK (202.7) · Operating profit/loss EBIT 42.4 MSEK (15.5) · Operating margin EBIT 13.2 % (7.6) · Profit after tax 37.8 MSEK (13.4) · Profit per share 3.05 SEK (1.32) January - December 2021 · Net turnover 1 186.9 MSEK (771.7) · Operating profit/loss EBIT 133.2 MSEK (65.6) · Operating margin EBIT 11.1 % (8.5) · Profit after tax 102.8 MSEK (45.2) · Profit per share 8.08 SEK (4.55) A word from the CEO Strong development. Record upon

Year-end report 1 January – 31 December 2021

As a result of the eased restrictions, all operations were able to re-open in what for the Group is the very important fourth quarter. All venues, productions and activity restaurants were able to run their operations to the fullest during the period with the exception of Oslo and Copenhagen, which were forced to close a few weeks before the Christmas break.FOURTH QUARTER 2021 2021 2020 2021 2020SEK million Oct–Dec Oct–Dec Jan–Dec Jan–DecNet sales 259 49 396

Year-end Report 1 October – 31 December 2021

· Despite pandemic related challenges: 30% sales growth and surgeries in 15 countries during 2021 · Episurf Medical’s first 510(k) submission completed in line with timetable. FDA review ongoing · Commercial organisation expanded with Head of Sales OUS, re-start of commercial activities following the end of the pandemic”Approaching the end of the pandemic is a relief on a human level, far beyond business life. However, it is fair to say that wearing the Episurf jersey during the pandemic has been extremely tough. Elective surgery has been severely hit, with experimental elective

Continued strong sales growth and improvement in operating income

PowerCell Sweden AB grew its sales by 49 percent during the fourth quarter 2021, from MSEK 38.2 to MSEK 56.8 compared with the same quarter last year. For the full year 2021, sales grew by 54 percent to MSEK 159.8 (103.5). Operating income improved to MSEK -23.9 (-29.5) due to continued increasing sales and strengthened gross margin.The fourth quarter 2021 was yet another very strong quarter for PowerCell Sweden AB with a new sales record for a single quarter. Sales for the full year also set a record. “Demand continued to be strong during the quarter with large-scale deliveries to

There are no items matching the current filter
There are no more items matching the current filter
Back to top